Pipeline

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways.

PARTNER
logo_sutro
logo_celgenesutro
logo_merck
Discovery
Preclinical Development
Clinical Phase
CD74 ADC, STRO-001

Indications: Multiple Myeloma, Aggressive and Indolent Lymphomas

IND-enabling
FolRa ADC, STRO-002

Indications: Ovarian and Endometrial Carcinoma

IND-enabling
Multiple oncology/
inmuno-oncology programs

 
 

BCMA ADC

Indications: Multiple Myeloma

IND-enabling
3 Undisclosed I/O bsAb

 

ADC's, multiple undisclosed targets

 

 
ADC's, multiple undisclosed targets